Waldenström's macroglobulinemia(patient information): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__  
__NOTOC__  
{{Waldenstrom's macroglobulinemia(patient information)}}
{{Waldenstrom's macroglobulinemia (patient information)}}
'''For the WikiDoc page for this topic, click [[ Waldenstrom's macroglobulinemia |here]]'''  
'''For the WikiDoc page for this topic, click [[ Waldenstrom's macroglobulinemia |here]]'''  



Revision as of 19:29, 17 January 2019

Template:Waldenstrom's macroglobulinemia (patient information) For the WikiDoc page for this topic, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Macroglobulinemia of Waldenstrom is a cancer of the B lymphocytes (a type of white blood cell). It is associated with the overproduction of proteins called IgM antibodies.[1]

What are the symptoms of Waldenström's macroglobulinemia?

Additional symptoms that may be associated with this disease:

  • Bluish skin discoloration
  • Fingers that change color upon pressure
  • Flank pain
  • Swollen glands

What causes Waldenström's macroglobulinemia?

Waldenstrom's macroglobulinemia is a result of a condition called lymphoplasmacytic lymphoma. The cause of the overproduction of the IgM antibody is unknown, but researchers believe it is made by lymphoma cells.

Overproduction of IgM causes the blood to become too thick. This is called hyperviscosity. It occasionally makes it harder for blood to flow through small blood vessels.

About 1,500 people in the United States are diagnosed with Waldenstrom's macroglobulinemia every year. Most people with this condition are over age 65, however, it may occur in younger people.

Diagnosis

Signs may include:

Tests may include:

Additional tests that may be done:

When to seek urgent medical care?

Call your health care provider if any symptoms of this disorder develop.

Treatment

  • Plasmapheresis - removes unwanted substances from the blood. In macroglobulinemia, it removes or reduces the high level of IgM, and is used to quickly control the symptoms caused by blood thickening.

What to expect (Outlook/Prognosis)?

The average survival is about 6.5 years. Some people live more than 10 years.

In some people, the disorder may produce few symptoms and progress slowly.

Possible complications

Sources

  1. "Macroglobulinemia of Waldenstrom: MedlinePlus Medical Encyclopedia".

Template:WH Template:WS